
Boehringer, Zealand's obesity drug did not raise heart risks in trial, data shows
来源:Reuters发布于 2026-11-09
Zealand Pharma and Boehringer Ingelheim's experimental obesity drug did not increase the risk of serious heart problems compared to a placebo in a late-stage trial, the companies said on Monday.
本文内容来自外部来源,点击「继续访问」将跳转到原始发布站点。